MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Interest Income
Income earned on cash, deposits, and investments held by the company.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Interest Income · Q3 FY2026 · quarter ended Sep 2026
Interest income growth accelerates
Q3 FY2026 interest income of $3.92M rose 69.9% year over year, ahead of the -60.0% change in trailing-twelve-month interest income. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at +210.0% a year.
Context
- Interest income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +69.9% holds above the trailing-twelve-month pace of -60.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 11.08M USD
- Year-over-year change
- +76.7%
- 3-year CAGR
- +210.0%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.08M | +76.7% |
| FY2024 | 2024-12-31 | 6.27M | +128.2% |
| FY2023 | 2023-12-31 | 2.75M | +638.7% |
| FY2022 | 2022-12-31 | 372K | — |
Interest Income vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -60.0% is the lowest of 8, against a peer median of +4.3%.
- Over three fiscal years its annual growth of +210.0% compares with a peer median of +25.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €56.37M EUR | +172.4% | +25.6% | 4.7% | |
| LTM Jun 2026 | $25.15M USD | -39.1% | +176.8% | — | |
| LTM Mar 2026 | $16.15M USD | +417.4% | -12.8% | — | |
| LTM Sep 2026 | $14.02M USD | -4.8% | +56.0% | 5.0% | |
KLRAKailera Therapeutics, Inc. | FY2025 | $11.05M USD | — | — | — |
| LTM Mar 2026 | $8.9M USD | +23.5% | +38.0% | 24713.9% | |
| LTM Mar 2026 | $4.77M USD | +4.3% | +22.5% | 1.5% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $4.16M USD | -60.0% | +210.0% | — |
| LTM Mar 2026 | $1.84M USD | -55.1% | +1.0% | — | |
| Peer median (excluding MBX) | — | +4.3% | +25.6% | 4.8% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 248K |
| Gross Profit | 0 | 0 | 0 | (248K) |
| Gross Margin | — | — | — | — |
| Research & Development | 21.4M | 28.53M | 57.42M | 79.16M |
| Selling, General & Admin | 3.76M | 6.78M | 10.78M | 18.9M |
| Operating Expenses | 25.16M | 35.31M | 68.19M | 98.06M |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| EBITDA | (25.71M) | (32.41M) | (61.68M) | (86.72M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (25.16M) | (35.31M) | (68.19M) | (98.06M) |
| Operating Margin | — | — | — | — |
| Interest Income | 372K | 2.75M | 6.27M | 11.08M |
| Interest Expense | 374K | 0 | 0 | 0 |
| Other Income / Expenses | (974K) | 2.75M | 6.27M | 11.08M |
| Income Before Tax | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.82) | (1.02) | (1.85) | (2.38) |
| EPS (Diluted) | (0.82) | (1.02) | (1.85) | (2.38) |
| Weighted Avg Shares | 31.85M | 31.85M | 33.39M | 36.51M |
| Weighted Avg Shares (Diluted) | 31.85M | 31.85M | 33.39M | 36.51M |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.